Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 21, 2016; 22(3): 1114-1130
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1114
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1114
Table 1 Published studies of prophylactic hyperthermic intraperitoneal chemotherapy in gastric cancer
| Ref. | Type of study | Inclusion criteria | Treatment arms(No. of Patients ) | Drugs used for IPC | Curative surgery | Complications | Post-op mortality | Survival | Peritoneal recurrence |
| Koga et al[65], 1988 | RCT | Serosa+ | Surgery + HIPEC (26) vs surgery alone (21) | MMC | 100% vs 100% | Leak 3.1% vs 7.1% | NA | 30 mo | NA |
| 83% vs 67% | |||||||||
| Hamazoe et al[67], 1994 | RCT | Serosa+ | Surgery + HIPEC (42) vs surgery alone (40) | MMC | 95% vs 88% | Leak 4.8% vs 7.5% | 0% vs 0% | 5-yr | 39% vs 59% (death due to PC) |
| 64% vs 52% | |||||||||
| Median survival | |||||||||
| 77 mo vs 66 mo | |||||||||
| Fujimura et al[72], 1994 | RCT | Serosa+ | Surgery + HIPEC (22) vs surgery + CNPP (18) vs surgery alone (18 controls) | MMC | NA | 30% vs 0% (perfusion vs surgery 40 pts vs 18) | NA | 3-yr | 9% vs 22% vs 22% (death due to PC) |
| CDDP | 68% vs 51% vs 23% (P < 0.01) | ||||||||
| Ikeguchi et al[73], 1995 | RCT | Serosa+ | Surgery + HIPEC (78) vs surgery alone (96) | MMC | 100% vs 100% | 1.2% vs 2.08% | NA | 5-yr | 35% vs 40% (death due to PC) |
| 51% vs 46% | |||||||||
| 5-yr | |||||||||
| 66% vs 44% | |||||||||
| (in 1-9 LN +) | |||||||||
| Fujimoto et al[74], 1999 | RCT | Serosa+ | Surgery + HIPEC (71) vs surgery alone (70) | MMC | 94.3% vs 92.8% | 2.8% vs 2.8% | 0% vs 0% | 2-yr | 1.4% vs 23% (P = 0.00008) |
| 88% vs 77% | |||||||||
| 4-yr | |||||||||
| 76% vs 58% | |||||||||
| 8-yr | |||||||||
| 62% vs 49% | |||||||||
| (P = 0.03) | |||||||||
| Hirose et al[75], 1999 | Prospective case control | Serosa+ | Surgery + HIPEC (15) vs surgery alone (40) | MMC | NA | 60% vs 42.5% | 0% vs 12.5% | 3-yr | 26% vs 45% |
| CDDP Etoposide | 49% vs 29% | ||||||||
| 5-yr | |||||||||
| 39% vs 17% | |||||||||
| Median survival | |||||||||
| 33 mo vs 22 mo (P = 0.01) | |||||||||
| Yonemura et al[76], 2001 | RCT | Serosa+ | Surgery + HIPEC (48) vs Surgery + CNPP (44) vs Surgery alone (47) | MMC | 100% vs 100% vs 100% | 19% vs 14% vs 19% | 4% vs 0% vs 4% | 5-yr | 13% vs 15% (HIPEC vs surgery) |
| CDDP | 61% vs 43% vs 42% | ||||||||
| Kim et al[77], 2001 | Prospective controlled study | Serosa+ | Surgery + HIPEC (52) vs surgery alone (51) | MMC | NA | 36.5% vs 33.3% | NA | 5-yr | 7.6% vs 25% (isolated PC) |
| 33% vs 27% | |||||||||
| 5-yr | |||||||||
| 42% vs 25% | |||||||||
| (in stage IIIB) |
- Citation: Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 2016; 22(3): 1114-1130
- URL: https://www.wjgnet.com/1007-9327/full/v22/i3/1114.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i3.1114